p53 Tumor Suppressor Gene Protein, Immunohistochemical, Paraffin Block
p53 Tumor Suppressor Gene Protein, Immunohistochemical, Paraffin Block
    
Number
481044
CPT
88360
Synonyms
Tumor Suppressor Gene, p53
Special Instructions
Please direct any questions regarding this test to Oncology Customer Service at 800-533-0567.
Specimen
Tumor (formalin-fixed, paraffin-embedded)
Volume
One paraffin block
Container
Paraffin block transport pouch
Collection
Specimen should be fixed in 10% neutral-buffered formalin. Optimum fixation time is 12-24 hours, not to exceed 48 hours.
Storage Instructions
Maintain specimen at room temperature.
Use
Alterations of the p53 tumor suppressor gene have been shown to serve as a powerful independent prognostic marker in a wide variety of tumor types such as colorectal,1,2 breast,3,4 prostate,5 and bladder.6 Multiple studies have supported the observation of alterations of p53 leading to tumor recurrence and shorter disease-free survival.7
Limitations
This procedure may be considered by Medicare and other carriers as investigational and, therefore, may not be payable as a covered benefit for patients.
Methodology
Immunohistochemistry (IHC)
FootnotesFootnotes - Updated April 16 2008
  1. Yamaguchi A, Kurosaka Y, Fushida S. et al. “Expression of p53 Protein in Colorectal Cancer and its Relationship to Short-Term Prognosis,” Cancer, 1992; 70(12):2778-2784.
  2. Starzynska T, Bromley M, Ghosh A. et al. “Prognostic Significance of p53 Overexpression in Gastric and Colorectal Carcinoma”, Br J Cancer, 1992; 66(3):558-562.
  3. Allred DC, Clark GM, Elledge R. et al. “Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast Cancer,” J Natl Cancer Inst, 1993; 85(3):200-206.
  4. Thor AD, Moore DH II, Edgerton SM. et al. “Accumulation of p53 Tumor Suppressor Gene Protein: An Independent Marker of Prognosis in Breast Cancers,” J Natl Cancer Inst, 1992; 84(11):845-855.
  5. Visakorpi T, Kallioniemi OP, Heikkinen A. et al. “Small Subgroup of Aggressive, Highly Proliferative Prostatic Carcinomas Defined by p53 Accumulation,” J Natl Cancer Inst, 1992; 84(11):883-887.
  6. Sarkis AS, Dalbagni G, Cordon-Cardo C. et al. “Nuclear Overexpression of p53 Protein in Transitional Cell Bladder Carcinoma: A Marker for Disease Progression,” J Natl Cancer Inst, 1993; 85(1):53-59.
  7. Fitzgibbons PL, Page DL, Weaver D. et al. “Prognostic Factors in Breast Cancer. College of American Pathologists Consensus Statement 1999,” Arch Pathol Lab Med, 2000; 124(7):966-978

Copyright © 2007 by Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved